Sodium thiosulfate - Fennec Pharmaceuticals

Drug Profile

Sodium thiosulfate - Fennec Pharmaceuticals

Alternative Names: PEDMARK; sodium-hyposulfite; STS - Fennec

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oregon Health & Science University
  • Developer Fennec Pharmaceuticals
  • Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Sensorineural hearing loss

Most Recent Events

  • 27 Mar 2018 Sodium thiosulfate - Fennec Pharmaceuticals receives Breakthrough Therapy status for Sensorineural hearing loss (In children, Prevention, Chemotherapy-induced) in USA
  • 26 Mar 2018 Fennec Pharmaceuticals intends to launch Sodium thiosulfate in the second half of 2019
  • 26 Mar 2018 Updated efficacy data from the phase III SIOPEL 6 trial in Sensorineural hearing loss released by Fennec Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top